MedWatch

Sanofi pivots toward boosters after Covid vaccine delays

Sanofi ends development of Covid Messenger-RNA vaccine.

(Bloomberg) --Sanofi will focus on supplying Covid-19 booster shots and fine-tuning its messenger RNA platform for the next pandemic after delays placed the drugmaker at least a year behind rivals in developing vaccines. 

That means halting the development of the company’s experimental messenger RNA shot, which would be redundant by the time it becomes available next year, according to Thomas Triomphe, executive vice president of Sanofi’s vaccines unit. 

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Trial banner

Latest news

See all jobs